Latest Distribution Agreements News

OMG Group has secured its maiden purchase order for premium SANDAI matcha in Australia, marking a promising start to a new high-margin revenue channel ahead of FY26.

HITIQ Limited has launched its PROTEQT™ concussion management system in North America, securing exclusive Canadian distribution rights and initiating a dual-channel market strategy targeting hockey’s vast ecosystem.

OMG Group has inked a five-year exclusive distribution agreement with SANDAI, a premium Japanese matcha producer, positioning itself to capture significant growth in Australia’s expanding matcha market.

Merino & Co. has secured a significant distribution agreement with a Shanghai-based omni-channel partner, committing to annual sales of approximately A$1.5 million and expanding its footprint in China’s luxury fashion market.

Zeotech Limited has signed a non-binding Letter of Intent with Bisley & Company to explore marketing and distribution of its high-reactivity metakaolin product, AusPozz™, across Australia and key international markets.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Merino & Co. initiates a new chapter with leadership changes and a strategic partnership to enter China’s premium apparel market, while investing heavily in growth during Q1 FY26.

Pure Hydrogen Corporation reported strong commercial momentum in the September 2025 quarter, securing multiple hydrogen vehicle orders across Australia and the US, expanding international distribution, and raising fresh capital to fuel growth.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.

SportsHero Limited has inked a pivotal two-year distribution agreement with PLDT Inc in the Philippines, raised $1.65 million through a private placement, and broadened its mobile gaming footprint across Southeast Asia with new content partnerships.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

Echo IQ Limited has advanced its EchoSolv heart failure solution towards FDA submission, driven by a landmark clinical validation study and a sharp rise in US platform adoption. Strategic partnerships and international expansion efforts underscore the company’s growing footprint in cardiology AI.